You will be given a definition of a task first, then an example. Follow the example to solve a new instance of the task.
Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Context: Architecturally, the school has a Catholic character. Atop the Main Building's gold dome is a golden statue of the Virgin Mary. Immediately in front of the Main Building and facing it, is a copper statue of Christ with arms upraised with the legend 'Venite Ad Me Omnes'. Next to the Main Building is the Basilica of the Sacred Heart. Immediately behind the basilica is the Grotto, a Marian place of prayer and reflection. It is a replica of the grotto at Lourdes, France where the Virgin Mary reputedly appeared to Saint Bernadette Soubirous in 1858. At the end of the main drive (and in a direct line that connects through 3 statues and the Gold Dome), is a simple, modern stone statue of Mary.
Question: To whom did the Virgin Mary allegedly appear in 1858 in Lourdes France?
Solution: Saint Bernadette Soubirous
Why? This is the correct answer. Because the question is asking for the name of the person and following sentence from the passage answers it: It is a replica of the grotto at Lourdes, France where the Virgin Mary reputedly appeared to Saint Bernadette Soubirous in 1858.

New input: Context: Rigel Pharmaceuticals Inc is developing fostamatinib, a prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406, for the potential treatment of autoimmune diseases such as rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and B-cell lymphomas. Syk is a key mediator of Fc and B-cell receptor signaling in inflammatory cells, such as B-cells, mast cells, macrophages and neutrophils. Preclinical studies of R-406 or fostamatinib demonstrated a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA. In a phase II clinical trial, fostamatinib treatment effectively improved American College of Rheumatology response rates in patients with RA. Preclinical studies and phase II trials also suggested the potential of using fostamatinib for the treatment of ITP and B-cell lymphomas, by increasing platelet counts and inducing response rates, respectively. Fostamatinib is orally bioavailable and was well tolerated in phase I and II trials, with the most common side effect being gastrointestinal symptoms. At the time of publication, phase II trials for fostamatinib were ongoing in patients with RA, ITP and B-cell lymphomas. The Syk inhibitor appears to be a promising therapeutic for immunological diseases, but further data are required to establish the efficacy and long-term safety of the drug in humans.
Question: Which enzyme is inhibited by a drug fostamatinib?
Solution:
spleen tyrosine kinase